Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag for prevention of T-DM1–induced thrombocytopenia in HER2-positive breast cancer
ChiCTR2500107984Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hetrombopag in breast cancer, sponsored by West China Hospital of Sichuan University. Primary endpoints: No grade 3 or higher thrombocytopenia during Herombopag treatment and No T-DM1 dose adjustment due to thrombocytopenia. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500107984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107984.